Targeting of DDR1 with antibody-drug conjugates has antitumor effects in a mouse model of colon carcinoma.

Animals Antineoplastic Agents, Immunological / pharmacology Caco-2 Cells Discoidin Domain Receptor 1 / antagonists & inhibitors Drug Delivery Systems HCT116 Cells HT29 Cells Humans Immunoconjugates / pharmacology Mice Mice, Inbred BALB C Mice, Nude Neoplasm Proteins / antagonists & inhibitors Neoplasms, Experimental / drug therapy Xenograft Model Antitumor Assays
antibody-drug conjugate colon cancer receptor tyrosine kinase resistance xenograft tumor model

Journal

Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230

Informations de publication

Date de publication:
09 2019
Historique:
received: 12 02 2019
revised: 03 05 2019
accepted: 20 05 2019
pubmed: 23 5 2019
medline: 1 5 2020
entrez: 23 5 2019
Statut: ppublish

Résumé

DDR1 has been identified as a cancer-associated receptor tyrosine kinase that is highly expressed in several malignancies relative to normal tissues. Clinically approved multi-kinase inhibitors, such as nilotinib, inhibit DDR1-mediated tumor growth in xenograft models, suggesting DDR1 might be a potential target for cancer treatments. Here, we employed an antibody-based strategy with a novel anti-DDR1 antibody-drug conjugate (ADC) for colon carcinoma treatment. We developed T

Identifiants

DOI: 10.1002/1878-0261.12520 PMID: 31116512 PMC: PMC6717758
pubmed: 31116512
doi: 10.1002/1878-0261.12520
pmc: PMC6717758
doi:

Substances chimiques

Antineoplastic Agents, Immunological 0
Immunoconjugates 0
Neoplasm Proteins 0
DDR1 protein, human EC 2.7.10.1
Discoidin Domain Receptor 1 EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1855-1873

Informations de copyright

© 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

Références

J Biol Chem. 2017 Apr 28;292(17):7162
pubmed: 28455409
ACS Chem Biol. 2013 Oct 18;8(10):2145-50
pubmed: 23899692
Clin Cancer Res. 2014 Dec 1;20(23):6045-58
pubmed: 25294907
Ther Adv Med Oncol. 2016 Jan;8(1):57-84
pubmed: 26753006
Drug Discov Today. 2015 Feb;20(2):255-61
pubmed: 25284748
BMC Cancer. 2017 Jan 31;17(1):87
pubmed: 28143619
Mol Cancer Ther. 2010 Oct;9(10):2700-13
pubmed: 20937595
Clin Cancer Res. 2004 Jul 1;10(13):4427-36
pubmed: 15240533
Nat Med. 2016 Mar;22(3):270-7
pubmed: 26855149
MAbs. 2014 Jul-Aug;6(4):838-51
pubmed: 24859229
Neurosurgery. 2000 Dec;47(6):1400-9
pubmed: 11126911
Eur J Cell Biol. 2016 Nov;95(11):503-512
pubmed: 27720259
Cell Adh Migr. 2018;12(4):363-377
pubmed: 29701112
J Biol Chem. 2004 Jul 23;279(30):31462-70
pubmed: 15136580
Structure. 2012 Apr 4;20(4):688-97
pubmed: 22483115
Cell Cycle. 2015;14(8):1129-30
pubmed: 25845022
J Med Chem. 2015 Apr 23;58(8):3287-301
pubmed: 25569119
Expert Opin Ther Targets. 2012 Jan;16(1):15-31
pubmed: 22239438
Clin Cancer Res. 2014 Sep 1;20(17):4436-41
pubmed: 24879797
Cancers (Basel). 2015 Sep 03;7(3):1758-84
pubmed: 26404379
J Biol Chem. 2003 May 9;278(19):16761-9
pubmed: 12611880
Blood. 2007 Dec 1;110(12):4055-63
pubmed: 17720881
Pathobiology. 1997;65(4):195-203
pubmed: 9396043
Eur J Pharmacol. 2008 Dec 3;599(1-3):44-53
pubmed: 18938156
J Mol Biol. 2009 Jan 16;385(2):432-45
pubmed: 19007791
Cell. 2010 Jun 25;141(7):1117-34
pubmed: 20602996
Signal Transduct Target Ther. 2017 May 19;2:17015
pubmed: 29263918
Am J Cancer Res. 2018 Apr 01;8(4):610-623
pubmed: 29736307
J Exp Clin Cancer Res. 2018 Feb 6;37(1):20
pubmed: 29409507
Blood. 2008 May 1;111(9):4797-808
pubmed: 18270328
Nat Rev Drug Discov. 2017 May;16(5):315-337
pubmed: 28303026
J Med Chem. 2013 Apr 25;56(8):3281-95
pubmed: 23521020
Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5677-81
pubmed: 8390675
Br J Cancer. 2007 Mar 12;96(5):808-14
pubmed: 17299390
Breast Care (Basel). 2017 Dec;12(6):401-408
pubmed: 29456473
MAbs. 2017 May/Jun;9(4):615-627
pubmed: 28281872
Clin Med Insights Oncol. 2017 Feb 16;11:1179554917690766
pubmed: 28469509
J Neurooncol. 2006 Feb;76(3):239-48
pubmed: 16234985
World J Gastroenterol. 2018 Sep 14;24(34):3834-3848
pubmed: 30228778
Oncol Lett. 2018 Mar;15(3):3403-3408
pubmed: 29467865
Ann Transl Med. 2017 Dec;5(23):462
pubmed: 29285495
J Control Release. 2010 Sep 15;146(3):264-75
pubmed: 20385184
Mol Cancer Ther. 2017 Nov;16(11):2473-2485
pubmed: 28864681
Cell Adh Migr. 2018;12(4):315-323
pubmed: 30187813
Matrix Biol. 2014 Feb;34:185-92
pubmed: 24361528
EMBO Mol Med. 2018 Apr;10(4):
pubmed: 29438985
Molecules. 2017 Aug 01;22(8):
pubmed: 28763044
Front Pharmacol. 2016 Mar 14;7:55
pubmed: 27014069
Cell. 2016 Jun 30;166(1):47-62
pubmed: 27368100
Int J Mol Sci. 2011 Jan 31;12(2):971-82
pubmed: 21541037
Mol Cancer Ther. 2015 Aug;14(8):1767-76
pubmed: 26184483
Sci Transl Med. 2015 Nov 18;7(314):314ra186
pubmed: 26582901
Oncogene. 2006 Sep 28;25(44):5994-6002
pubmed: 16652150

Auteurs

Yiran Tao (Y)

State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.

Ruixue Wang (R)

State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.

Qinhuai Lai (Q)

State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.

Mengdan Wu (M)

State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.

Yuxi Wang (Y)

Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.

Xiaohua Jiang (X)

State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.

Lishi Zeng (L)

State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.

Shijie Zhou (S)

State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.

Zhongping Li (Z)

State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.

Tinghan Yang (T)

State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China.

Yuqin Yao (Y)

West China School of Public Health and Healthy Food Evaluation Research Center/No. 4 West China Teaching Hospital, Sichuan University, Chengdu, China.

Yangping Wu (Y)

State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Department of Clinical Research Management, West China Hospital, Sichuan University, Chengdu, China.

Lin Yu (L)

State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Department of Clinical Laboratory, Mianyang Central Hospital, Mianyang, China.

Yuyin Fu (Y)

State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.

Weirong Lai (W)

State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.

Yujia Peng (Y)

State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.

Ying Lu (Y)

State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.

Zhixiong Zhang (Z)

State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.

Cuiyu Guo (C)

State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.

Guangbing Zhang (G)

State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.

Lantu Gou (L)

State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.

Jinliang Yang (J)

State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Guangdong Zhongsheng Pharmaceutical Co., Ltd., Dongguan, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Targeting of DDR1 with antibody-drug...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Antinéoplasiques immunologiques › Targeting of DDR1 with antibody-drug...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules Caco-2 › Targeting of DDR1 with antibody-drug...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs immunologiques › Récepteur mitogène › Récepteurs à domaine discoïdine › Récepteur-1 à domaine discoïdine › Targeting of DDR1 with antibody-drug...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Systèmes de délivrance de médicaments › Targeting of DDR1 with antibody-drug...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Cellules HCT116 › Targeting of DDR1 with antibody-drug...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules HT29 › Targeting of DDR1 with antibody-drug...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Targeting of DDR1 with antibody-drug...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Facteurs immunologiques › Immunoconjugués › Targeting of DDR1 with antibody-drug...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Targeting of DDR1 with antibody-drug...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée BALB C › Targeting of DDR1 with antibody-drug...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souches mutantes de souris › Souris nude › Targeting of DDR1 with antibody-drug...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Targeting of DDR1 with antibody-drug...
questionsmedicales.fr › Techniques d'investigation › Modèles animaux › Tumeurs expérimentales › Targeting of DDR1 with antibody-drug...
questionsmedicales.fr › Techniques d'investigation › Transplantation tumorale › Tests d'activité antitumorale sur modèle de xénogreffe › Targeting of DDR1 with antibody-drug...